Publications by authors named "Mark Rozenbaum"

Claim this Profile
C
Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children.
Ahuva Averin, Derek Weycker, Rotem Lapidot, Mark H Rozenbaum, Liping Huang

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conceptual Methodological Framework for Incorporating Antimicrobial Resistance Considerations in Economic Models for Pneumococcal Conjugate Vaccines.
Mark H Rozenbaum, Maria J Tort, Ruth Chapman, Katherine K Perez, Desmond Dillon-Murphy

Infect Dis Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare providers' preferences for pediatric pneumococcal vaccination recommendations in the United States.
Jeffrey Vietri, Kelley Myers, Liping Huang, Vincenza Snow, Mark H Rozenbaum

Expert Rev Vaccines· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disparities in invasive pneumococcal disease, pneumonia, and otitis media among US children by comorbidity profile and insurance status.
Rotem Lapidot, Ahuva Averin, Derek Weycker, Liping Huang, Jeffrey Vietri, Mark H Rozenbaum

Front Public Health· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Approach to Estimate the Impact of PCV20 Immunization in Children by Incorporating Indirect Effects to Generate the Number Needed to Vaccinate.
Mark H Rozenbaum, Maria J Tort, Blair Capitano, Ruth Chapman, Desmond Dillon-Murphy

Vaccines (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-life pneumonia and subsequent risk of respiratory disease among commercial-insured and medicaid-insured children with and without high-risk conditions.
Ahuva Averin, Stephen I Pelton, Derek Weycker, Liping Huang, Jeffrey Vietri, Mark H Rozenbaum

Respir Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US.
Aleksandar Ilic, Maria J Tort, Alejandro Cane, Raymond A Farkouh, Mark H Rozenbaum

Vaccines (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric Pneumococcal Conjugate Vaccine and Dosing Schedule Perceptions Among Health Care Providers and Caregivers in Germany, France, Spain, and Greece.
Johnna E Perdrizet, Mark H Rozenbaum, Matthew J Heffler

Infect Dis Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory Syncytial Virus Sequelae Among Adults in High-Income Countries: A Systematic Literature Review and Meta-analysis.
Egbe Ubamadu, Estefania Betancur, Bradford D Gessner, Sonia Menon, Hilde Vroling, Mark Rozenbaum

Infect Dis Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions.
Mark H Rozenbaum, Erica Chilson, Raymond Farkouh, Liping Huang, Alejandro Cane

Infect Dis Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13.
Mark H Rozenbaum, Liping Huang, Alejandro Cane, Adriano Arguedas, Ruth Chapman

J Med Econ· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
Mark H Rozenbaum, Liping Huang, Johnna Perdrizet, Alejandro Cane, Adriano Arguedas

Vaccine· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile.
Derek Weycker, Ahuva Averin, Linnea Houde, Kevin Ottino, Kimberly Shea, Mark Rozenbaum

Infect Dis Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric Respiratory Syncytial Virus Diagnostic Testing Performance: A Systematic Review and Meta-analysis.
Chukwuemeka Onwuchekwa, Jessica Atwell, Laura Mora Moreo, Sonia Menon, Belen Machado, Mark Rozenbaum

J Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis.
Chukwuemeka Onwuchekwa, Laura Mora Moreo, Sonia Menon, Belen Machado, Daniel Curcio, Mark Rozenbaum

J Infect Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data.
Mark H Rozenbaum, Elizabeth Begier, Samantha K Kurosky, Jo Whelan, Danai Bem

Infect Dis Ther· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective.
Xiuyan Li, Sophie Warren, Mark H Rozenbaum, Johnna Perdrizet

Infect Dis Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United States.
Mark H Rozenbaum, Jen Judy, Diana Tran, Kari Yacisin, Samantha K Kurosky

Infect Dis Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.
Marcel H Schöttler, Friso B Coerts, Maarten J Postma, Cornelis Boersma, Mark H Rozenbaum

Value Health· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Response to: Letter to the Editor Regarding 'Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age'.
Mark H Rozenbaum, Johnna Perdrizet, Xiuyan Li, Matt D Wasserman, Lindsay R Grant

Infect Dis Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death.
Huihua Li, Mark Rozenbaum, Michelle Casey, Marla B Sultan

Cardiology· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries.
Rosa Lauppe, Johan Liseth Hansen, Anna Fornwall, Katarina Johansson, Mark H Rozenbaum

ESC Heart Fail· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy.
Mark H Rozenbaum, Diana Tran, Rahul Bhambri, Jose Nativi-Nicolau

Am J Cardiovasc Drugs· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource use of patients with transthyretin amyloid cardiomyopathy.
Rosa Lauppe, Johan Liseth Hansen, Anna Fornwall, Katarina Johansson, Mark H Rozenbaum

ESC Heart Fail· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?
Maarten J Postma, Declan Noone, Mark H Rozenbaum, John A Carter, Marc F Botteman

Orphanet J Rare Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis